Business Context and Reporting Period
Mira Pharmaceuticals, Inc. (NASDAQ: MIRA), an emerging growth company incorporated in Florida, filed this Form 8-K on September 15, 2025. The filing reports a material event under Item 8.01 regarding positive preclinical data for its drug candidate, Ketamir-2, in a post-traumatic stress disorder (PTSD) model.
Key Financial Metrics
This filing is a Current Report (Form 8-K) focused on a scientific milestone and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change reported is the successful completion of a proof-of-concept validation study for Ketamir-2. In a rat model of PTSD using the Single Prolonged Stress (SPS) paradigm, oral administration of Ketamir-2 reversed stress-induced behaviors, including anxiety, avoidance, and despair, restoring them to levels observed in non-stressed animals.
Outlook, Management Commentary, and Risks
- Study Progress: The initial validation supports the study design, and a larger follow-on PTSD study is currently ongoing.
- Clinical Status: Ketamir-2 is being evaluated in an ongoing Phase 1 clinical trial for neuropathic pain, where it has demonstrated a favorable safety profile to date.
- Drug Profile: Ketamir-2 is an orally bioavailable new molecular entity targeting the NMDA receptor (PCP site) with low affinity. It is designed to mimic ketamine's efficacy while minimizing dissociative side effects.
- Regulatory Status: The U.S. Drug Enforcement Administration (DEA) has concluded that Ketamir-2 would not be considered a controlled substance under the Controlled Substances Act.
- Prior Data: Previous preclinical studies indicated superior efficacy compared to ketamine, pregabalin, and gabapentin in neuropathic pain models.
Investor Verification Checklist
- Verify the timeline and enrollment status of the ongoing larger follow-on PTSD study.
- Review the latest data from the ongoing Phase 1 clinical trial for neuropathic pain to confirm the continued favorable safety profile.
- Confirm the company's current cash runway and capital requirements given the lack of revenue-generating products mentioned in this filing.
- Monitor future filings for the specific statistical significance and sample size details of the reported PTSD animal study.